Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Frontier IP portfolio update: The Vaccine Group, Exscientia and a trading update

Frontier IP portfolio update: The Vaccine Group, Exscientia and a trading update

Frontier IP Group PLC's (LON:FIPP) Neil Crabb talks to Proactive London's Katie Pilbeam about their recent announcements including on The Vaccine Group, one of the companies in its investment portfolio, which has appointed a chief executive officer - Dr Jeremy Salt.

As outlined in the Group’s interim results statement released on 24 March 2021, the Group enjoyed a strong first half to the financial year with the Group’s portfolio continuing to show strong commercial and technical progress.

And Crabb explains the Exscientia investment of up to $525m led by SoftBank.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK